NSE: LAURUSLABS | BSE: 540222

Strong Performer, Getting Expensive

Download real time

1090.50 32.20 (3.04%)

Near 52W High of ₹1141.00

2.5M NSE+BSE Volume

NSE 14 Jan, 2026 3:31 PM (IST)

58,871.4

Market Cap

High in industry

Beta 1Year

Very High Volatility

Board Meeting

The next board meeting for Laurus Labs is on 23 Jan 2026 for the purpose of Quarterly Results See details

Laurus Labs Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for LAURUSLABS, BSE:540222 Laurus Labs Ltd.

Search Inside the pdf :

Laurus Labs Ltd.

28 Oct 2025

1090.50

3.04%

Strong quarter led by CDMO growth, ARV recovery, and margin expansion; continued investment supports long-term multi-modal strategy.

Sell: Laurus Labs Ltd.

Target

Deven Choksey

Laurus Labs continues to shift toward a CDMO-led, technology-focused business model, leveraging its ARV portfolio as a steady cash generator.

Laurus Labs has gained 91.99% in the last 1 Year

Laurus Labs Ltd.

24 Oct 2025

1090.50

3.04%

Laurus Labs

Buy: Laurus Labs Ltd.

Recommendation Target

ICICI Direct

Q2FY26 Upbeat numbers across parameters - Sales stood at 1654 crore, reflecting a ~35% YoY growth and a growth of ~5.3% QoQ. The CDMO business saw impressive growth of 58% YoY, reaching 471 crore. Generic FDF also grew 58% YoY to 518 crore and the Generic APIs segment grew ~11% YoY to 617 crore. EBITDA stood at 403 crore with a margin of 24.4%, marking a significant improvement of 979 basis points YoY. PAT stood 193.8 crore, driven by a favourable product mix and strong operational performance....

Laurus Labs Ltd. has an average target of 888.00 from 5 brokers.

Laurus Labs Ltd.

23 Oct 2025

1090.50

3.04%

Healthy momentum in CDMO/FDF; earnings upcycle intact

Buy: Laurus Labs Ltd.

Target

Motilal Oswal

Laurus Lab (LAURUS) delivered yet another better-than-expected quarter with a 6%/18%/38% beat on revenue/EBITDA/PAT. Higher formulation sales (FDF; backed by robust ARV revenue), a superior mix in the CDMO segment, and improving operating leverage led to a strong 2QFY26 performance.

Laurus Labs Ltd. is trading above all available SMAs

Laurus Labs Ltd.

01 Aug 2025

1090.50

3.04%

Solid Q1FY26 execution underpins confidence in CDMO-led growth strategy

Sell: Laurus Labs Ltd.

Deven Choksey

Revenue: Consolidated revenue for the quarter increased by 31.4% YoY (-8.8% QoQ) to INR 15,696 Mn., significant beat on our estimates (+15.0%), driven by strong outperformance in the Custom Synthesis and the Generic FDF segment.

Number of FII/FPI investors increased from 293 to 340 in Sep 2025 qtr.

Laurus Labs Ltd.

20 May 2025

1090.50

3.04%

Laurus Labs Ltd

Buy: Laurus Labs Ltd.

AUM Capital

Laurus Labs Ltd (Laurus) was incorporated in the year 2005 as an Anti-Retroviral (ARV) Active Pharmaceutical Ingredient (API) company. (ARV drugs are medications used to treat HIV infection and prevent its progression). Later, it diversified its operations by entering into Formulations and Contract Development Manufacturing Operations (CDMO) services to become an integrated pharma company. Currently, Laurus's...

Laurus Labs has gained 91.99% in the last 1 Year

Laurus Labs Ltd.

25 Apr 2025

1090.50

3.04%

Laurus Labs (HOLD): Visibility of Operating Leverage

Hold: Laurus Labs Ltd.

Recommendation Target

BOB Capital Markets Ltd.

Revenue/EBITDA/PAT exceeded our estimates by 8.4%/32.6%/110.3%; EBITDA margin surpassed our estimate by 440 bps

Laurus Labs has gained 91.99% in the last 1 Year

Laurus Labs Ltd.

24 Apr 2025

1090.50

3.04%

FDF/CDMO drives earnings; ends FY25 on strong note

Buy: Laurus Labs Ltd.

Target

Motilal Oswal

Laurus Lab (LAURUS) delivered a second consecutive quarter with betterthan-expected performance, led by healthy traction in the Formulation (FDF)/API segment. Despite softer-than-expected performance in the CDMO business during 4QFY25, the quarterly sales run rate continued its uptrend.

Laurus Labs has gained 91.99% in the last 1 Year

Laurus Labs Ltd.

27 Jan 2025

1090.50

3.04%

Laurus Labs (SELL): Margin guidance shifted from 20% to closer to 20% for FY25E

Sell: Laurus Labs Ltd.

Target

BOB Capital Markets Ltd.

Revenue/EBITDA/PAT exceeded our estimates by 10.5%/46.6%/227%. EBITDA margin surpassed our estimate by 500bps

Laurus Labs has gained 32.37% in the last 6 Months

Laurus Labs Ltd.

25 Jan 2025

1090.50

3.04%

Beat on earnings; green shoots visible

Buy: Laurus Labs Ltd.

Target

Motilal Oswal

Laurus Lab (LAURUS) significantly beat our earnings estimates in 3QFY25, led by a scale-up in the CDMO segment. Commercial supplies (including launch quantities) led to strong 89% YoY growth in CDMO sales for the quarter.